4/8
06:00 pm
ibrx
IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role
Low
Report
IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role
4/8
04:50 pm
ibrx
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman
Low
Report
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman
4/8
12:00 pm
ibrx
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Low
Report
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
4/8
12:00 pm
ibrx
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Low
Report
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
4/8
11:12 am
ibrx
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
Neutral
Report
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
4/8
08:03 am
ibrx
ImmunityBio (IBRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
Medium
Report
ImmunityBio (IBRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
4/7
09:50 pm
ibrx
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Low
Report
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
4/7
04:49 pm
ibrx
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
4/7
04:30 pm
ibrx
ImmunityBio, Inc. Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Low
Report
ImmunityBio, Inc. Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
4/7
04:00 pm
ibrx
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky
Low
Report
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky
4/7
01:49 pm
ibrx
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
Low
Report
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
4/7
12:10 pm
ibrx
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
Low
Report
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
4/7
12:00 pm
ibrx
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Low
Report
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
4/7
10:01 am
ibrx
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Low
Report
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
4/7
09:00 am
ibrx
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
Low
Report
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
4/7
08:34 am
ibrx
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
Low
Report
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
4/7
01:57 am
ibrx
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm
Medium
Report
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm
4/6
08:10 pm
ibrx
Why ImmunityBio Stock Slumped on Monday [Yahoo! Finance]
Low
Report
Why ImmunityBio Stock Slumped on Monday [Yahoo! Finance]
4/6
05:38 pm
ibrx
ImmunityBio (IBRX) Faces FDA Warning, BTIG Stays Positive [Yahoo! Finance]
Medium
Report
ImmunityBio (IBRX) Faces FDA Warning, BTIG Stays Positive [Yahoo! Finance]
4/6
04:00 pm
ibrx
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misled on Drug Efficacy: Levi & Korsinsky
Medium
Report
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misled on Drug Efficacy: Levi & Korsinsky
4/6
01:53 pm
ibrx
ImmunityBio And 2 Insider Picks For Promising Growth [Yahoo! Finance]
Low
Report
ImmunityBio And 2 Insider Picks For Promising Growth [Yahoo! Finance]
4/6
09:05 am
ibrx
ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
Medium
Report
ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
4/6
07:46 am
ibrx
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance [Yahoo! Finance]
Medium
Report
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance [Yahoo! Finance]
4/6
07:30 am
ibrx
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
Low
Report
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
4/6
07:12 am
ibrx
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Low
Report
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit